SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo
Open Access
- 4 February 2026
- journal article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
Abstract
Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder with increasing worldwide incidence and prevalence. While current treatment options alleviate part of the socioeconomic burden of this disease, new biomarkers and safer therapeutic approaches are needed to combat intestinal inflammation. Class-3 semaphorins (sema3A-3G) have emerged as important regulators of some biological functions underlying inflammation. For instance, SEMA3B protects against tissue damage in arthritis. However, the association of this protein with UC and its involvement in the onset of intestinal inflammation remains elusive. Methods: To close that knowledge gap, we performed a comprehensive transcriptomic analysis of different patient cohorts. Moreover, we investigated the therapeutic efficacy of Sema3B in vivo . Results: Our findings revealed that the expression of SEMA3B was downregulated in IBD patients compared with healthy controls. Similarly, non-responder UC patients to infliximab showed reduced transcript levels of that class-3 semaphorin before receiving the treatment. Unfortunately, the administration of recombinant Sema3B to mice subjected to DSS-acute colitis did not modify the course of the disease. Conclusions: Therefore, SEMA3B appears to be an interesting biomarker in the context of intestinal inflammation, which deserves further validation in larger cohorts. Nonetheless, based on our in vivo results, the implication of this factor in the development of colitis seems to be minimal.Keywords
This publication has 36 references indexed in Scilit:
- Semaphorin3C identified as mediator of neuroinflammation and microglia polarization after spinal cord injuryiScience, 2024
- Neutrophils: from IBD to the gut microbiotaNature Reviews Gastroenterology & Hepatology, 2023
- Cytokine responsive networks in human colonic epithelial organoids unveil a molecular classification of inflammatory bowel diseaseCell Reports, 2022
- Central Role of Semaphorin 3B in a Serum‐Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2022
- Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2020
- Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel diseaseEBioMedicine, 2019
- Expression of semaphorin 3E is suppressed in severe asthmaJournal of Allergy and Clinical Immunology, 2017
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2014
- Aggravation of Different Types of Experimental Colitis by Depletion or Adhesion Blockade of NeutrophilsGastroenterology, 2007
- A crucial role for macrophages in the pathology of K/B × N serum‐induced arthritisEuropean Journal of Immunology, 2005